Type 1 Diabetes Market to reach USD 63.5 billion by 2032 and grow at a CAGR of 7.82%.

The Type 1 diabetes market is changing with innovations in insulin delivery systems, continuous glucose monitoring (CGM) technologies, and advanced research into stem cell therapies and immunomodulation. The latest trend in this market is one of the most exciting artificial pancreases. Automated insulin delivery systems use a CGM device and an insulin pump to allow precise, real-time matching between glucose levels and the delivery of insulin. The Medtronic MiniMed 670G was the first of FDA-approved hybrid closed-loop systems that would adjust and automatically change insulin administration levels to maintain optimal glucose control. 4 Tandem Diabetes Care\'s tX2 with Control-IQ technology advances this further by including automatic correction boluses, meaning it keeps enhancing control of glucose levels while decreasing patient intervention.